Devon Robotics Announces Per I.V. Dose Pricing Option for Its i.v.STATION™ Robot

Business Wire, May 05, 2009

KING OF PRUSSIA, Pa. -- Devon Robotics today announced an optional pricing structure for its i.v.STATION™ robot that eliminates the need for scarce capital funding. Healthcare providers may now acquire i.v.STATION for $1USD per dose through a creative financing plan that avoids large, “up-front” capital expenditures. Included in this simple, fee-per-dose model is the utilization of i.v.STATION, hardware installation, clinical implementation, interface engineering, all licensing fees and ongoing service and maintenance.

“The combination of the $1 per dose pricing option with i.v.STATION’s container flexibility, small foot-print, no-charge Profile option, and fail-safe architecture is redefining the competitive environment for non-hazardous IV Robotics for both batch and patient-specific doses. At a time where our competitors are retreating, we keep advancing the cause of safe and cost-effective IV Robotics and software automation solutions,” stated John A. Bennett, M.D., CEO of Devon Robotics.

i.v.STATION represents a revolutionary approach in the quest for safe, accurate, efficient, cost effective, and ready-to-administer IVs. Constructed around a scalable, distributed, and fail-safe architecture, i.v.STATION offers unprecedented container flexibility, life-critical patient safety, and robotic precision and performance and it may be deployed in a variety of locations, including central and satellite pharmacies and patient care areas, due to its self-contained form, ISO Class 5 environment, and small “foot-print.” Healthcare providers may, for the first time, choose a robotic configuration that suits their needs, rather than being forced into the dated alternative of “one-size-fits-all, million-dollar-plus” robots.

“Our plan is to start an i.v.STATION Profile beta implementation in one of our Adult Intensive Care Units. We expect that having this type of technology near the point-of-care will improve turn-around-time issues and will provide immediate life-critical coverage where our pharmacists cannot be physically present on a 24/7 basis. We expect that the i.v.STATION Profile Robot will deliver IV Medications to our Nursing staff, after they have been safely reviewed and approved remotely by our staff pharmacists, including an audit trail of all i.v.STATION Profile compounding steps and a digital picture review of the medication vials utilized in the compounding process,” said Scott Evans, Pharm.D., Chief Operating Officer, USC University Hospital and USC Norris Cancer Hospital.

Whether a pharmacy chooses a single or multiple i.v.STATION configurations, it will benefit from fully automated compounding while producing its ready-to-administer IV doses with a variety of syringe, bag, vial, and tamper-evident caps from diverse medical suppliers such as Baxter, B|Braun, Becton Dickinson, Hospira, IMF, Covidien, and Terumo. i.v.STATION also supports “just-in-time IV filling” to reduce urgent turn-around-time issues of life-critical patients while avoiding premium prices associated with pre-filled bags and syringes.

About Devon Robotics

Devon Robotics is a medical robotics company that is revolutionizing the way hazardous drugs and life-critical IV medications are prepared in North America. The company is the exclusive North American distributor of Health Robotics’ CytoCare™, the world’s first and only automated robotic system for the safe preparation of hazardous, patient-specific intravenous medications, and i.v.STATION™, an automated robotic solution for the safe compounding of life-critical non-hazardous intravenous medications and injectables. Devon Robotics is a Devon International Group company headquartered in King of Prussia, Pennsylvania. Visit www.devonrobotics.com for more information.

About Health Robotics

Health Robotics is the global leading supplier of life-critical intra-venous medication preparation, compounding, and dispensing Robots, with forty-five-times more units sold than all of its competitors combined, and providing healthcare facilities in four continents with robotics technology and software automation solutions. The world-leading solutions CytoCare™ [hazardous IVs] and i.v.STATION™ [non-hazardous IVs] have and will greatly contribute to ease global hospitals’ and clinics’ growing pressures to improve patient safety through the effective and efficient production of sterile, accurate, and ready-to-administer IVs, to eliminate life-threatening drug-exchange errors, to decrease other medication errors and contamination risks, and to work more efficiently, increase throughput, reduce waste, and contain costs.